MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Total Assets 2011-2026 | ZOM
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 M | 207 M | 253 M | 280 M | 280 M | 63 K | 4.18 M | 6.03 M | 5.22 M | 82.1 K | 145 K | 212 K | 97.3 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 280 M | 63 K | 89.5 M |
Quarterly Total Assets Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 M | 136 M | 143 M | 207 M | 214 M | 220 M | - | 253 M | 275 M | 275 M | 280 M | 280 M | 282 M | 275 M | 278 M | 280 M | 278 M | 280 M | 280 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 4.18 M | 4.18 M | 4.18 M | 4.18 M | 6.03 M | 6.03 M | 6.03 M | 6.03 M | 5.22 M | 5.22 M | 5.22 M | 5.22 M | 4.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 282 M | 4.18 M | 134 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.47 | 0.92 % | $ 86.3 M | Canada |
 |
Jupiter Wellness
JUPW
|
41 M | - | - | $ 33.6 M | USA |
 |
Assertio Holdings
ASRT
|
267 M | $ 19.37 | 0.83 % | $ 124 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.38 | 0.56 % | $ 1.96 B | Canada |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.0 | -0.18 % | $ 108 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.2 | 1.03 % | $ 45 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.56 | 1.1 % | $ 1.35 B | Canada |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.23 | - | $ 421 M | USA |
 |
Evolus
EOLS
|
226 M | $ 4.14 | 2.61 % | $ 267 M | USA |
 |
Harrow Health
HROW
|
399 M | $ 35.5 | 0.54 % | $ 1.3 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.4 | 1.63 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.3 | 2.68 % | $ 303 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 22.49 | -0.93 % | $ 1.04 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 6.93 | -0.86 % | $ 274 M | USA |
 |
Rockwell Medical
RMTI
|
57.1 M | $ 0.95 | -0.73 % | $ 34.2 M | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.94 | 5.86 % | $ 46.9 M | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 7.74 | 3.34 % | $ 677 M | USA |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.36 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.36 | -0.42 % | $ 2.93 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 6.61 | 0.84 % | $ 4.08 B | Canada |
 |
Veru
VERU
|
60.4 M | $ 2.34 | 2.18 % | $ 316 M | USA |
 |
Viatris
VTRS
|
50 B | $ 13.36 | -0.6 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.72 | -1.17 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
31 M | $ 0.61 | -3.16 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
37.7 M | $ 2.08 | 4.0 % | $ 24.1 M | USA |